Genetic study of pancreatic cancer in Ashkenazi Jewish patients
Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients
This study is trying to see how common certain genetic mutations are in Ashkenazi Jewish patients with pancreatic cancer to help improve screening and treatment options for those at risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT01102569 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the frequency of BRCA1 and BRCA2 genetic mutations in Ashkenazi Jewish patients diagnosed with pancreatic cancer. By analyzing about 100 patients, the study seeks to identify the prevalence of specific mutations that may influence the risk and management of pancreatic cancer. The findings could lead to improved early screening and treatment options for individuals with hereditary pancreatic cancer. Additionally, the study will explore various disease-related factors such as survival rates and treatment decisions.
Who should consider this trial
Good fit: Ideal candidates for this study are Ashkenazi Jewish individuals diagnosed with pancreatic cancer.
Not a fit: Patients who are not of Ashkenazi Jewish descent or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early detection and treatment strategies for pancreatic cancer in patients with hereditary risk factors.
How similar studies have performed: Other studies have shown success in identifying genetic mutations related to pancreatic cancer, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with pancreatic cancer. * Patients are of Ashkenazi Jewish descent. * Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154). Exclusion Criteria: * Inability to provide informed consent. * Under the age of 18 years old.
Where this trial is running
New York, New York
- Columbia University Medical Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Fay Kastrinos, MD — Columbia University
- Study coordinator: Fay Kastrinos, MD
- Email: fk18@columbia.edu
- Phone: 212-305-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.